Ab Initio Joins Groundbreaking Project to Develop World’s First Multi-Organ Radiation Protectant
The revolutionary drug is designed to safeguard internal organs from harmful radiation, offering protection to professionals such as astronauts
We are excited to announce that Ab Initio Pharma has joined a pioneering project funded by the Australian government to develop the world’s first multi-organ pharmaceutical radiation protectant. This innovative solution, aimed at enhancing defence capabilities and providing protection to civilians, is being developed in collaboration with the University of Adelaide and SAiGENCI (South Australian ImmunoGENomics Cancer Institute). The manufacturing development collaboration with Ab Initio is led by Dr. Agnieszka Kumorkiewicz-Jamro and Prof. ChunXia Zhao, under a comprehensive program of pharmaceutical development for the ‘Daisy Project’, led by Prof. Christopher Sweeney (Director of SAiGENCI).
Ab Initio’s role in the project will involve translating the novel protectant into a clinic-ready formulation, and scaling it for cGMP (current Good Manufacturing Practice) manufacturing. The $395,000 seed grant from Australia's Economic Accelerator (AEA) program will fund the research and development to ensure the drug meets the rigorous standards required for clinical trials. This drug is designed to safeguard internal organs from harmful radiation, offering protection to professionals such as astronauts, aircrew, healthcare workers, and emergency responders exposed to radiation risks. The success of this project will mark a significant milestone in pharmaceutical advancements for both defence and civilian applications.
About Ab Initio Pharma
Ab Initio Pharma specializes in GMP-compliant manufacturing for clinical trials, with expertise in respiratory, nasal, oral, and topical dosage forms. Our facilities ensure high-quality production of clinical-grade materials through stringent process control and regulatory compliance, helping to bring innovative therapies to market efficiently and safely. Learn more at www.ab-initio-pharma.com
